Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
MS Carlino, K Gowrishankar, CAB Saunders… - Molecular cancer …, 2013 - AACR
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP–ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
MS Carlino, K Gowrishankar, CA Saunders… - Molecular Cancer …, 2013 - europepmc.org
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
[PDF][PDF] Antiproliferative Effects of Continued Mitogen-Activated
PKPI following Acquired - 2013 - researchgate.net
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP–ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
[PDF][PDF] Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in …
MS Carlino, K Gowrishankar, CAB Saunders… - Mol Cancer …, 2013 - scholar.archive.org
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP–ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
[PDF][PDF] Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in …
MS Carlino, K Gowrishankar, CAB Saunders, GM Pupo… - Mol Cancer Ther, 2013 - Citeseer
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP–ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
MS Carlino, K Gowrishankar… - Molecular cancer …, 2013 - pubmed.ncbi.nlm.nih.gov
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
MS Carlino, K Gowrishankar… - Molecular Cancer …, 2013 - researchers.mq.edu.au
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
[PDF][PDF] Antiproliferative Effects of Continued Mitogen-Activated
PKPI following Acquired - 2013 - academia.edu
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP–ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …